Announcements Trials
Browse Landscape

Phase

Phase 2 5Phase 1/2 2Phase 1 2Phase 2/3 1

Status

Completed 1Active not recruiting 1

Sponsor Class

NIH 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 1Genitourinary 1

Conditions

Urinary Bladder Neoplasms 1Leukemia, Hairy Cell 1Carcinoma in Situ 1

Interventions

Specimen Handling 150pembrolizumab 132Magnetic Resonance Spectroscopy 120Cyclophosphamide 118Biopsy 106fludarabine 90Nivolumab 61Carboplatin 55Radiotherapy 49Cisplatin 49Gemcitabine 48venetoclax 43Paclitaxel 43Cetuximab 40fludarabine phosphate 39Ipilimumab 36Fluorouracil 35atezolizumab 34Bevacizumab 33durvalumab 30Radiation 30Oxaliplatin 29X-Rays 28Leucovorin 28Dexamethasone 28Azacitidine 27Irinotecan 26Cytarabine 26Radiosurgery 24Injections 24

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1 × Diphenhydramine × 90 days × Clear all
NCT03805932 2026-05-19

Moxetumomab Pasudotox-tdfk (Lumoxiti(TM)) and Either Rituximab (Rituxan(R)) or Ruxience for Relapsed Hairy Cell Leukemia

National Institutes of Health Clinical Center (CC)

Phase 1 Active not recruiting
18 enrolled 15 charts
Other hematologic neoplasm

Leukemia, Hairy Cell

NCT03258593 2026-03-17

Durvalumab and Vicineum in Subjects With High-Grade Non-Muscle-Invasive Bladder Cancer Previously Treated With Bacillus Calmette-Guerin (BCG)

National Institutes of Health Clinical Center (CC)

Phase 1 Completed
15 enrolled 21 charts
Genitourinary

Urinary Bladder Neoplasms, Carcinoma in Situ

Data powered by HemOnc (CC BY 4.0) Colophon âš¡